Nakamura, Yoshio

写真a

Affiliation

School of Medicine, Department of Dermatology （Shinanomachi）

Position

Assistant Professor/Senior Assistant Professor
Page Top ▲

Career 【 Display / hide 】

  • 2006.04
    -
    2008.03

    Tokyo Kosei Nenkin Hospital

  • 2008.04
    -
    2009.06

    Department of Dermatology, Keio University School of Medicine

  • 2009.07
    -
    2011.10

    Ogikubo Hospital

  • 2011.10
    -
    2014.06

    Department of Dermatology, Keio University School of Medicine

  • 2014.07
    -
    2016.06

    National Cancer Center Hospital

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2000.04
    -
    2006.03

    Kanazawa University, School of Medicine, Department of Medicine

    University, Graduated

  • 2014.04
    -
    2018.03

    Keio University, Graduate School of Medicine, Medical Science

    Graduate School, Withdrawal after completion of doctoral course requirements

Page Top ▲

Academic Degrees 【 Display / hide 】

  • Ph.D., Keio University, Coursework, 2019.01

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • Medical License, 2006.04

  • The Japanese Dermatological Association Board certified dermatologist, 2011.10

  • Japanese Board of Cancer Therapy certified General Clinical Oncologist, 2014.04

  • The Japanese Dermatological Association Board certified Skin Cancer Educator, 2017.04

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Dermatology

Page Top ▲

Research Keywords 【 Display / hide 】

  • Skin Cancer

  • SUrgical Oncology

Page Top ▲
 

Papers 【 Display / hide 】

  • Outcomes in extramammary Paget's disease patients with brain metastasis: a retrospective analysis.

    Fusumae T, Fukuda K, Hirai I, Nakamura Y, Tanese K, Iwata T, Funakoshi T

    Journal of the American Academy of Dermatology  2020.05

    ISSN  0190-9622

  • Weekly docetaxel monotherapy for metastatic extramammary Paget’s disease: Retrospective single-institute analysis

    Nakamura Y., Tanese K., Hirai I., Fukuda K., Kawakami Y., Amagai M., Funakoshi T.

    Journal of Dermatology （Journal of Dermatology)  47 （ 4 ） 418 - 422 2020.04

    ISSN  03852407

    　View Summary

    © 2020 Japanese Dermatological Association Monthly docetaxel (DTX) monotherapy is the first-line regimen that is preferably used for metastatic extramammary Paget’s disease (EMPD). However, the high-dose DTX regimen frequently causes severe hematological adverse events (AE). To overcome such safety concerns, a weekly low-dose DTX monotherapy has been proposed for use in the treatment of various cancer types. In this study, we aimed to evaluate the feasibility and efficacy of weekly DTX (25 mg/m2) monotherapy for metastatic EMPD by retrospectively analyzing the clinical courses of 14 patients treated with this regimen. Weekly DTX monotherapy was well tolerated and all patients completed the treatment schedule without treatment withdrawal, dose reduction or treatment-related death. While five cases (35.7%) experienced hematological AE, their severity was mild. The response rate was 35.7% (5/14 cases), which included five partial responses. The mean progression-free survival (PFS) and overall survival were 7.1 (95% confidence interval [CI], 5.1–9.1) and 26.4 months (95% CI, 16.7–36.1), respectively. Furthermore, the median PFS was 7.3 months (95% CI, 4.5–10.0) in patients aged 65 years and younger and 7.1 months (95% CI, 4.4–9.9) in patients older than 65 years. These results suggest that weekly DTX monotherapy may be a useful regimen that has a high treatment continuation rate with low levels of hematological toxicity, regardless of the patient’s age for metastatic EMPD.

  • Metastatic cutaneous squamous cell carcinoma in liver successfully treated with partial hepatectomy and adjuvant irinotecan chemotherapy

    Asahina Y., Nakamura Y., Tanese K., Hirai I., Fukuda K., Amagai M., Funakoshi T.

    In Vivo （In Vivo)  34 （ 2 ） 825 - 828 2020

    ISSN  0258851X

    　View Summary

    © 2020 International Institute of Anticancer Research. All rights reserved. Background: The management of distant metastatic cutaneous squamous cell carcinoma (cSCC) relies mainly on chemotherapies and radiotherapy. Management of patients with cSCC with surgically resectable distant metastatic lesions is not clear. Case Report: A 59-year-old male had 4×10 cmsized cSCC on the perianal skin with inguinal lymph node metastasis. Surgical resection was performed followed by radiation and adjuvant carboplatin and farmorubicin combination therapy. Six months later, 25 mm-sized solitary metastatic nodule arose on the liver. Base on his favorable overall condition fulfilling the criteria of tumor resectability for the treatment of tumors in liver and having good performance status, laparoscopic partial hepatectomy and six courses of adjuvant irinotecan therapy were performed. The surgical margin was negative and the patient has maintained complete remission for over 3 years. Conclusion: The clinical course of the present case suggests that surgical approaches should also be considered as candidate additional therapy for resectable distant metastatic cSCC.

  • Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease

    Nakamura Y., Tanese K., Hirai I., Amagai M., Kawakami Y., Funakoshi T.

    British Journal of Dermatology （British Journal of Dermatology)  181 （ 3 ） 535 - 543 2019.09

    ISSN  00070963

    　View Summary

    © 2019 British Association of Dermatologists Background: Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma affecting the genitals and axillary regions. As metastasis of these tumours is itself rare, solid disease management strategies have not been established. Serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21-1 (CYFRA 21-1) levels have been identified as candidate biomarkers for tumour progression in EMPD. Objectives: To determine the accuracy of and the correlation between these markers in patients with EMPD. Methods: Serum CEA and CYFRA 21-1 levels were examined in 30 patients with EMPD treated at Keio University Hospital, and compared against clinical information. Both assays were performed at the time of diagnosis, during the postoperative observation period, and following systemic treatment in those with confirmed metastasis. Serum levels were then correlated with tumour progression status and treatment responses. Results: Normal levels for both assays were observed in all 11 patients with primary localized disease (100%). In patients with metastatic disease the CEA positivity rate was 79% (15 of 19 patients), with a rate of 63% (12 of 19 patients) for CYFRA 21-1. Changes in CEA and CYFRA 21-1 levels were statistically independent; however, using a combined view, elevated levels of either marker improved the positivity rate to 95% (18 of 19 patients). Use of both markers also correlated well with treatment responses. Conclusions: The combination of CEA and CYFRA 21-1 is useful for predicting metastasis and treatment response in patients with EMPD, especially in those who only have elevation of a single marker. What's already known about this topic?. Serum levels of carcinoembryonic antigen (CEA) and cytokine 19 fragment 21-1 (CYFRA 21-1) have been shown to be elevated in patients with extramammary Paget disease (EMPD). Elevation of serum CEA levels is associated with tumour progression of EMPD. A single small study reported that serum CYFRA 21-1 levels are elevated in patients with EMPD with lymph node metastasis. What does this study add?. Serum CEA and CYFRA 21-1 were present in 79% and 63% of 19 cases of metastatic EMPD, respectively. Elevations of CEA and CYFRA 21-1 were statistically independent. CEA and CYFRA 21-1 combination assays were positive in 95% of cases of metastatic EMPD. What is the translational message?. Combination assays with CEA and CYFRA 21-1 are useful for monitoring treatment response in patients with metastatic EMPD, particularly in those with elevation of either marker.

  • Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease

    Hirai I., Tanese K., Nakamura Y., Ishii M., Kawakami Y., Funakoshi T.

    Oncologist （Oncologist)  24 （ 6 ） e394 - e396 2019.06

    ISSN  10837159

    　View Summary

    © AlphaMed Press 2019 Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required. In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80% partial responses, including two patients who were refractory to taxane- and/or platinum-based regimens. In terms of safety, four patients who were able to continue treatment exhibited acceptable tolerability. This is the first regimen to combine taxane and anthracycline. When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anthracycline in combination with taxane constitutes a key chemotherapeutic regimen. Given our results, we speculate both drugs are critical chemotherapeutic agents for the treatment of metastatic EMPD.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • Analysis Of The Appropriate Margin Of Pigmented Bcc: A Single Institute Retrospective Study In Japan

    Yoshio Nakamura

    World congress on cancers of the skin (Sydney) , 

    2018.08

  • Retrospective Study Of Chemotherapy Using Carboplatin And Epirubicin For Advanced Epithelial Malignancy Of The Skin. World congress on cancers of the skin

    Yoshio Nakamura

    World congress on cancers of the skin (Sydney) , 

    2018.08

  • Pretreatment prognostic factors and early markers for outcome in advanced melanoma treated with nivolumab

    Yoshio Nakamura

    ESMO 2016 congress (Copenhagen) , 

    2016.10
    , 

    ESMO

  • Outcomes of local treatment for malignant melanoma brain metastases: a single institution retrospective study

    Yoshio Nakamura

    European Cancer Congress (Vienna) , 

    2015.09

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Analysis of the three-dimensional structure of Extramammary Paget's disease using the tissue clearing method

    2021.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists , Principal investigator

Page Top ▲